Klinikum Chemnitz

Hospital


Location: Chemnitz, Germany (DE) DE

ISNI: 0000000403894214

ROR: https://ror.org/04wkp4f46

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial (2019) Janning M, Müller V, Vettorazzi E, Cubas-Cordova M, Gensch V, Ben-Batalla I, zu Eulenburg C, et al. Journal article Quality of life of short-statured children born small for gestational age or idiopathic growth hormone deficiency within one year of growth hormone treatment (2019) Quitmann J, Bloemeke J, Silva N, Bullinger M, Witt S, Akkurt I, Dunstheimer D, et al. Journal article Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients (2019) Nabieva N, Häberle L, Brucker SY, Janni W, Volz B, Löhberg C, Hartkopf AD, et al. Journal article Clinical Characteristics and Outcome in IDH1/2 Mutant AML Patients - Analysis of 3898 Newly Diagnosed Patients with Acute Myeloid Leukemia (2018) Middeke JM, Rollig C, Kramer M, Kramer A, Bochtler T, Scholl S, Hochhaus A, et al. Conference contribution EZH2 Mutations and Impact on Clinical Outcome Analyzed in 1604 Patients with Acute Myeloid Leukemia (2018) Stasik S, Middeke JM, Kraemer M, Rollig C, Kramer A, Scholl S, Hochhaus A, et al. Conference contribution Comorbidities Are Frequent in Older Patients with De Novo Acute Lymphoblastic Leukemia (ALL) and Correlate with Induction Mortality: Analysis of More Than 1200 Patients from GMALL Data Bases (2018) Wermann WK, Viardot A, Kayser S, Alakel N, Elmaagacli A, Faul C, Fiedler W, et al. Conference contribution Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL plus Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study (2018) Hochhaus A, Saussele S, Baerlocher GM, Bruemmendorf TH, Burchert A, La Rosee P, Hasford J, et al. Conference contribution Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma (2018) Schäfer N, Proescholdt M, Steinbach JP, Weyerbrock A, Hau P, Grauer O, Goldbrunner R, et al. Journal article Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients (2018) Roellig C, Kramer M, Gabrecht M, Haenel MH, Herbst R, Kaiser U, Schmitz N, et al. Journal article Extension study to the open-label, multi-center, expanded access study of everolimus in patients with advanced neuroendocrine tumors (2017) Doerffel Y, Kullmann F, Lammert F, Quietzsch D, Schöfl C, Schuppert F, Weber M, et al. Conference contribution